AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03321513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Deferred Aflibercept Group
Description: Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique.
Study NCT05126979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split Influenza Vaccine
Study NCT05126979 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02807740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
Study NCT02807740 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional rehabilitation program
Description: In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
Study NCT02593305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g/day) for 4 weeks
Study NCT02593305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets Placebo
Description: Nitrate deficient beetroot powder (10g/day) for 4 weeks
Study NCT02496351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS INTERVENTION
Description: 24 hours of TENS treatment in the immediately postoperative of limb amputation
Study NCT02344251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MEMS Cap
Description: MEMS Track Cap records when the medication bottle is opened and closed
Study NCT02344251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ID-Cap
Description: ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
Study NCT00041106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00041106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00041106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO
Study NCT00041106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01040195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate, Hydroxychloroquine
Description: Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
Study NCT01040195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
Study NCT01689246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 150 mg/day
Description: TRx0237 75 mg tablets will be administered twice daily.
Study NCT01689246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 250 mg/day
Description: TRx0237 125 mg tablets will be administered twice daily.
Study NCT01689246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study NCT01833624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen® AF
Description: Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
Study NCT01833624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sondalis® HP
Study NCT02657213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 640G with smartguard activated
Description: Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
Study NCT02657213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimed 640G with smartguard off
Description: Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO 300u/kg, subcutaneous injection, qd
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltitrexed
Description: 3mg/m2 q3w
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 3mg/m2 q3w
Study NCT03823079 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
Study NCT03823079 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
Study NCT03823079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIL-11
Description: rhIL-11 50ug/kg, subcutaneous injection, qd
Study NCT04042766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser vaginal treatment
Description: Er:YAG laser
Study NCT04042766 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laser vaginal treatment
Description: Er:YAG laser
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone Gel (Fortesta) 40mg daily.
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Testosterone Gel (Fortesta) 40mg daily.
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Alendronate (Fosamax) 70mg every week.
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate (Fosamax) 70mg every week.
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alendronate
Description: A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
Study NCT01460654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone
Description: Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
Study NCT02899559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message
Description: Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
Study NCT04726644 — intervention group
Intervention type: PROCEDURE
Intervention: hernia repair
Description: different methods for hernia repair
Study NCT01512069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Health Planner on diet and exercise
Description: URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors.
Study NCT01512069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored booklet on exercise and diet
Description: The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
Study NCT00885742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human)
Description: Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion.
Study NCT02589236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: GSNOR inhibitor
Study NCT02589236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control sample with only capsule excipients and fillers
Study NCT02935504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM)
Description: PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention
Study NCT02935504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCPAP for Moms
Description: MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
Study NCT06422104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
Study NCT04804670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power device A
Description: Oral hygiene regimen completed daily
Study NCT04804670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power device B
Description: Oral hygiene regimen completed daily
Study NCT04804670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Oral Hygiene
Description: Oral hygiene regimen completed daily
Study NCT02997644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education
Description: The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer.
Study NCT02997644 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Group
Description: Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
Study NCT03755869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Study NCT02773212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine
Description: Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
Study NCT02773212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
Study NCT02773212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management
Description: Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
Study NCT02773212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
Study NCT02773212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for d-amphetamine)
Description: 60 mg of riboflavin and cornstarch as needed.
Study NCT01676896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma in-school class
Study NCT01676896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Day Camp
Study NCT01676896 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Promotion in-school class
Study NCT00672581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg, Oral tablet, single dose
Study NCT02259751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00003145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00003145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00003145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT00003145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT00003145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT00003145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT00003145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study NCT00003145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03803709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: inulin given at different dosis from day 3 to day 20
Study NCT03803709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrine given at different dosis from day 3 to day 20
Study NCT02984436 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
Study NCT02984436 — intervention group
Intervention type: BEHAVIORAL
Intervention: HEART Score
Description: The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
Study NCT01021436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin inhalation solution (BAY41-6551)
Description: Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
Study NCT04581005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
Study NCT01578707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofatumumab
Description: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)
Study NCT01578707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
Study NCT02274298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD feedback and tools
Description: people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
Study NCT00623103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsule
Description: Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
Study NCT00623103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
Study NCT03353909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new crosslinked hyaluronan gel
Description: At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
Study NCT02044172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: radical prostatectomy
Study NCT02044172 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal radiation therapy
Description: Conformal radiation therapy, external beam
Study NCT02044172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active monitoring
Description: Active monitoring of Prostate specific antigen levels and disease surveillance
Study NCT03979248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days.
Study NCT03979248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Specified dose on specified days.
Study NCT04039542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT)
Description: Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
Study NCT01442909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and pemetrexed
Description: docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
Study NCT04371250 — intervention group
Intervention type: OTHER
Intervention: Survey and Questionnaire
Description: Resilience and Loneliness questionnaires
Study NCT04635124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog visit
Description: An visitor visits the participant with a dog
Study NCT04635124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog visit
Description: An visitor visits the participant with a dog
Study NCT04635124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encourage to engage in activity
Description: In each visit the visitor invites the participant to engage in an activitty
Study NCT04635124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Encourage to engage in activity
Description: In each visit the visitor invites the participant to engage in an activitty
Study NCT02286570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope used for endotracheal intubation
Study NCT02286570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope used for endotracheal intubation